Printer Friendly

U.S. BIOSCIENCE REPORTS FOURTH QUARTER RESULTS OF OPERATIONS

 U.S. BIOSCIENCE REPORTS FOURTH QUARTER RESULTS OF OPERATIONS
 WEST CONSHOHOCKEN, Pa., Feb. 18 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS) today reported revenues of $4,007,400 and a net loss of $1,692,900 or $.04 per share for its fourth quarter ended Dec. 31, 1991. The 1991 fourth quarter results compare to revenues of $1,407,200 and a net loss of $1,281,500 or $.04 per share for the same period of the prior year.
 Revenues for the full year 1991 were $11,077,100, and the net loss was $6,540,100 or $.18 per share. The 1991 results compare to a net loss of $4,924,900 or $.15 per share on revenues of $3,452,600 for the prior year.
 Sales of Hexalen(R), a treatment for ovarian cancer, amounted to $3,348,400 for the year. The company had no sales during the prior year. Investment income, the only other revenue component, increased as a result of a larger investment portfolio due to the company's second public offering in May 1991.
 Research and development expenses increased principally due to work pertaining to the Ethyol(R) New Drug Application (NDA) which was submitted to the Food and Drug Administration in September 1991; the Trimetrexate NDA which the company anticipates will be submitted in 1992; research relating to the company's other drug compounds and the manufacture of clinical supplies.
 Selling expenses increased principally as a result of maintaining a sales force for a full year in the United States and expenses relating to the advertising and marketing of Hexalen. Administrative expenses increased over the prior year primarily due to the addition of management personnel and other key employees.
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company engaged in the development and commercialization of drugs to increase the survival and quality of life of patients with cancer and allied diseases. The company's portfolio includes ten compounds, four of which are in Phase III of clinical testing; and one product, Hexalen, is on the market in the United States.
 U.S. BIOSCIENCE INC.
 Condensed Statement of Operations
 12 Months Ended Three Months Ended
 Dec. 31, Dec. 31,
 1991 1990 1991 1990
 Revenues
 Sales $3,348,400 -- $728,300 --
 Investment
 Income, Net 7,728,700 3,452,600 3,279,100 1,407,200
 Total Revenues 11,077,100 3,452,600 4,007,400 1,407,200
 Expenses
 Cost of Sales 762,100 -- 124,000 --
 Selling &
 Administrative 6,876,300 3,668,800 2,417,600 1,424,200
 Research &
 Development 9,928,500 4,479,500 3,158,700 1,211,300
 Interest Expense 50,300 229,200 -- 53,200
 Total
 Expenses 17,617,200 8,377,500 5,700,300 2,688,700
 Net Loss $(6,540,100) $(4,924,900) $(1,692,900) $(1,281,500)
 Net Loss Per Share $(0.18) $(0.15) $(0.04) $(0.04)
 Wt. Avg. No. of
 Shares (A) 37,094,500 32,686,600 39,078,500 33,863,428
 (A) After giving effect to a 2-for-1 stock split paid in the form of a dividend to common shareholders on Jan. 17, 1992.
 -0- 2/18/92
 /CONTACT: Robert I. Kriebel, 215-832-4503; or David E. Lanks, 215-832-4523, both of U.S. Bioscience/
 (UBS) CO: U.S. Bioscience ST: Pennsylvania IN: MTC SU: ERN


RM -- SJ004 -- 0038 02/18/92 14:47 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1992
Words:569
Previous Article:SCANA CORPORATION ANNOUNCES HIGHER EARNINGS FROM OPERATIONS FOR FOURTH QUARTER AND FULL YEAR 1991
Next Article:GENERAL MOTORS 7.625 PERCENT NOTES DUE 1997 RATED 'A+' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
U.S. BIOSCIENCE REPORTS SECOND QUARTER RESULTS OF OPERATIONS
U.S. BIOSCIENCE REPORTS RESULTS FOR FOURTH QUARTER AND YEAR
U.S. BIOSCIENCE ANNOUNCES SECOND QUARTER RESULTS
U.S. BIOSCIENCE ANNOUNCES FOURTH QUARTER RESULTS, INCLUDING $.26 PER SHARE ONE-TIME CHARGE
U.S. BIOSCIENCE ANNOUNCES FIRST QUARTER RESULTS
U.S. BIOSCIENCE ANNOUNCES SECOND QUARTER RESULTS
IVX BioScience Announces 1998 Second Quarter Results
MedImmune Sets New Revenue and Earnings Records.
Baxter's Third Quarter Earnings Rise 17 Percent.
MedImmune Sets New Revenue and Earnings Records.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters